DCTH Stock Risk & Deep Value Analysis
Delcath Systems Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About DCTH Stock
We analyzed Delcath Systems Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DCTH through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
DCTH Risk Analysis & Red Flags
What Could Go Wrong
The company could struggle with rapid commercial adoption and favorable reimbursement for the Hepzato Kit, leading to continued cash burn and dilutive capital raises. Slow sales growth relative to expenses, especially given recent EPS cuts, would suppress the stock price and make it challenging to achieve profitability within the 3-5 year horizon.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Low
Competitive
Low
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
High trailing P/E (130-177x) and forward P/E (114x) reflecting significant future growth already priced in.
- ⚠
Significant EPS estimate cuts for FY2026 by HC Wainwright ($0.58 to -$0.86), indicating challenges to profitability.
- ⚠
Lack of granular cash flow and detailed balance sheet metrics in provided research, hindering comprehensive financial health assessment.
- ⚠
Company's reliance on a single approved product (Hepzato Kit) for its growth trajectory.
Upcoming Risk Events
- 📅
Slower-than-expected commercial adoption of Hepzato Kit
- 📅
Delay or unfavorable outcome in reimbursement negotiations
- 📅
Negative results or delays in future clinical trials for label expansion
When to Reconsider
- 🚪
Exit if quarterly Hepzato Kit revenue growth decelerates significantly (<10% QoQ growth) or sales forecasts are repeatedly missed.
- 🚪
Sell if the company announces further highly dilutive capital raises without commensurate revenue or pipeline progress.
- 🚪
Reconsider if gross margins start to consistently decline, indicating pricing pressure or rising production costs.
Unlock DCTH Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Delcath Systems Inc (DCTH) Do?
Market Cap
$346.66M
Sector
Healthcare
Industry
Medical Devices
Employees
96
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
Visit Delcath Systems Inc WebsiteInvestment Thesis
Delcath Systems possesses a compelling, unique asset in the Hepzato Kit, addressing a critical unmet medical need in metastatic ocular melanoma to the liver. Its exclusive FDA approval and early commercial traction provide a strong foundation for future market leadership and potential 10x growth, contingent on successful execution of its commercial strategy, favorable reimbursement, and future label expansion into broader oncology indications. Despite significant financial risks, the unique competitive advantage and high market upside potential warrant an aggressive investment stance.
Is DCTH Stock Undervalued?
Unlock the full AI analysis for DCTH
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
DCTH Price Targets & Strategy
12-Month Target
$24.70
Bull Case
$31.00
Bear Case
$15.00
Valuation Basis
Based on 8x projected FY2026 sales of $108M (extrapolating from Q4 2025 rev and TTM) implies $864M market cap / 34.98M shares.
Entry Strategy
Consider dollar-cost averaging in the $9.00-$10.00 range, leveraging any dips for accumulation.
Exit Strategy
Take partial profits at $20.00 and $25.00, with a stop-loss order placed if the stock consistently breaks below $8.50 (a key support level, implying loss of momentum).
Portfolio Allocation
7-10% for aggressive risk tolerance, reflecting the high-growth, high-risk nature of an early-stage biotech with a unique product.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is DCTH Financially Healthy?
Valuation
P/E Ratio
177.13
Forward P/E
114.30
Profitability
Net Margin
3.17%
Return on Equity
2.63%
EPS
$0.06
Other
Beta (Volatility)
0.47
Does DCTH Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The unique FDA approval creates a strong initial barrier. Durability will depend on successful commercial rollout, continued positive clinical data for label expansion, and establishing standard-of-care status before competitors can develop similar or superior liver-directed therapies.
Moat Erosion Risks
- •Emergence of competitive systemic or liver-directed therapies with superior efficacy or fewer side effects.
- •Challenges in expanding the label to broader indications, limiting the TAM.
- •Patent expiry or successful challenges to existing intellectual property.
DCTH Competitive Moat Analysis
Sign up to see competitive advantages
DCTH Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, driven by analyst optimism and recent institutional accumulation, but typically a niche stock for retail discussion.
Institutional Sentiment
Positive, evidenced by 61.12% institutional ownership, Daniel Kaufman's 5.08% stake on March 18, 2026, and Propel Bio Management's 94% stake increase (March 5, 2026). Analyst consensus is Moderate/Strong Buy with high price targets.
Insider Activity (Form 4)
Form 4 filings were reported on March 3, 2026 and March 6, 2026, though specific buy/sell activity and value were not detailed in available reports.
Options Flow
Normal options activity (no specific data provided for unusual flow).
Earnings Intelligence
Next Earnings
Estimated May 2026
Surprise Probability
Medium (Q4 beat, but Q1 2026 EPS consensus is negative, potentially setting a low bar for an EPS beat, while revenue could surprise positively).
Historical Earnings Pattern
Q4 2025 earnings beat on both revenue and EPS, generally leading to positive market sentiment, but previous historical patterns are not explicitly detailed.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (due to unique FDA approval for mOM to the liver with percutaneous hepatic perfusion, there's no direct best-in-class competitor)
Market Share Trend
Gaining (starting from a low base in its uniquely approved indication).
Valuation vs Peers
Trading at a significant premium on trailing and forward P/E, which is common for early-stage biotechs with high growth potential, but warrants careful monitoring given recent EPS estimate cuts.
Competitive Advantages
- •Proprietary Hepzato Kit and CHEMOSAT system for liver-directed chemotherapy.
- •Unique FDA approval for metastatic ocular melanoma to the liver, addressing a critical unmet medical need.
- •Positive Phase 2 CHOPIN trial results supporting the platform's efficacy.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive DCTH Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated May 2026)
- •Participation at Society of Interventional Radiology 2026 meeting (Apr 11-15, 2026)
Medium-Term (6-18 months)
- •Accelerated commercial adoption and market penetration of Hepzato Kit
- •Favorable reimbursement decisions and expanded coverage for Hepzato Kit
- •Updates on potential label expansion studies beyond mOM to the liver
Long-Term (18+ months)
- •Establishment of Hepzato Kit as standard of care for mOM to the liver
- •Successful label expansion into other primary or metastatic liver cancers
- •Long-term revenue growth and achievement of sustained profitability
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for DCTH?
- ✓
Acceleration in Hepzato Kit revenue growth and positive cash flow trends.
- ✓
Announcements of new clinical trials, regulatory milestones, or label expansions.
- ✓
Sustained institutional accumulation and analyst target upgrades.
Bull Case Analysis
See what could go right with Premium
Competing with DCTH
See how Delcath Systems Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Delcath Systems Inc DCTH | $346.7M | 6.2 | 177.1 | $70.2M | 3.2% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Delcath Systems Inc (DCTH)?
As of April 2, 2026, Delcath Systems Inc has a DVR Score of 6.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Delcath Systems Inc?
Delcath Systems Inc's market capitalization is approximately $346.7M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Delcath Systems Inc use?
DCTH is the ticker symbol for Delcath Systems Inc. The company trades on the NCM.
What is the risk level for DCTH stock?
Our analysis rates Delcath Systems Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of DCTH?
Delcath Systems Inc currently has a price-to-earnings (P/E) ratio of 177.1. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is Delcath Systems Inc's revenue growing?
Delcath Systems Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is DCTH stock profitable?
Delcath Systems Inc has a profit margin of 3.2%. The company is profitable but margins are modest.
How often is the DCTH DVR analysis updated?
Our AI-powered analysis of Delcath Systems Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 2, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for DCTH (Delcath Systems Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.